| Literature DB >> 24407537 |
B K Goyal1, B C Kalmath2, Ramesh Kawar2, Anil Sharma2, Bhushan Khemnar3, Hrishikesh Rangnekar4.
Abstract
New generation DES are effectively used in all spectrum of coronary artery diseases (CAD) and are replacing earlier DES and BMS. Biolimus A9™-eluting stent is a new generation DES containing the anti-proliferative drug biolimus A9™ incorporating a biodegradable abluminal coating that leaves a polymer-free stent after drug release enhancing strut coverage while preventing neointimal hyperplasia. A retrospective data analysis was done in patients treated with DES, with a major share of Biolimus A9™ (BA9™) drug-eluting stents (DES) at Bombay Hospital, Mumbai. A total of 158 patients with 219 lesions were treated with DES, comprising Biolimus A9-eluting stent and others and the major adverse cardiac events (MACE) rate and stent thrombosis (ST) at 1, 6, 12 months and 24 months were analyzed. Mace rate was 3.16% for average follow-up of 19 months. There were 3 cases of ST (2 of acute and 1 of subacute onset) and one non-cardiac death reported during this time. This retrospective data demonstrates good one- and two-year clinical safety and efficacy of DES, especially of BioMatrix stents in real world setting.Entities:
Keywords: Abluminal; BioMatrix; Biodegradable polymer; Biolimus A9; Major adverse cardiac events
Mesh：
Substances：
Year: 2013 PMID： 24407537 PMCID： PMC3905255 DOI： 10.1016/j.ihj.2013.10.014
Source DB: PubMed Journal: Indian Heart J ISSN： 0019-4832